Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic CancersGlobeNewsWire · 3 days ago
Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to LabcorpBenzinga · 5 days ago
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to LabcorpGlobeNewsWire · 5 days ago
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026GlobeNewsWire · Oct 15, 2026
ADMA Biologics (NASDAQ:ADMA) & Myriad Genetics (NASDAQ:MYGN) Critical AnalysisDefense World · Oct 12, 2026
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyPRNewsWire · Oct 8, 2026Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | -$0.06 | -$0.25 | Miss |
| May 5, 2026 | -$0.06 | -$0.09 | Miss |
| Feb 23, 2026 | -$0.02 | $0.04 | Beat |
| Nov 3, 2025 | -$0.01 | -$0.13 | Miss |
| Aug 5, 2025 | -$0.01 | $0.05 | Beat |
| May 6, 2025 | -$0.05 | -$0.03 | Beat |